Trials

# Nutritional Intervention Preconception and During Pregnancy to Maintain Healthy Glucose Metabolism and Offspring Health ("NiPPeR"): study protocol for a randomised controlled trial

Keith M. Godfrey[1,2*], Wayne Cutfield[3,4], Shiao-Yng Chan[5,6], Philip N. Baker[3,7], Yap-Seng Chong[5,6] and NiPPeR Study Group

## Abstract

**Background:** Improved maternal nutrition and glycaemic control before and during pregnancy are thought to benefit the health of the mother, with consequent benefits for infant body composition and later obesity risk. Maternal insulin resistance and glycaemia around conception and in early pregnancy may be key determinants of maternal physiology and placental function, affecting fetal nutrient supply and maternal-feto-placental communications throughout gestation, with implications for later postnatal health.

**Methods/design:** This double-blind randomised controlled trial will recruit up to 1800 women, aged 18–38 years, who are planning a pregnancy in the United Kingdom (UK), Singapore and New Zealand, with a view to studying 600 pregnancies. The primary outcome is maternal glucose tolerance at 28 weeks' gestation following an oral glucose tolerance test. Secondary outcomes include metabolic, molecular and health-related outcomes in the mother and offspring, notably infant body composition. Participants will be randomly allocated to receive a twice-daily control nutritional drink, enriched with standard micronutrients, or a twice-daily intervention nutritional drink enriched with additional micronutrients, myo-inositol and probiotics, both demonstrated previously to assist in maintaining healthy glucose metabolism during pregnancy. Myo-inositol is a nutrient that enhances cellular glucose uptake. The additional micronutrients seek to address deficiencies of some B-group vitamins and vitamin D that are both common during pregnancy and that have been associated with maternal dysglycaemia, epigenetic changes and greater offspring adiposity. Women who conceive within a year of starting the nutritional drinks will be followed through pregnancy and studied with their infants at six time points during the first year of life. Blood, urine/stool, hair and cheek swabs will be collected from the mothers for genetic, epigenetic, hormone, nutrient and metabolite measurements, and assessments of the mother's body composition, anthropometry, health, diet and lifestyle will be made. Infants will also undergo hair, cheek swab, urine and stool sampling for similar biological measurements; infant body composition will be assessed and feeding recorded.

(Continued on next page)

\* Correspondence: kmg@mrc.soton.ac.uk
[1]NIHR Southampton Biomedical Research Centre, University Hospital Southampton, NHS Foundation Trust, Southampton, UK
[2]MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Mailpoint 95, Southampton SO16 6YD, UK
Full list of author information is available at the end of the article

(Continued from previous page)

**Discussion:** There is an increasing focus on the need to optimise maternal nutrition starting prior to conception. This trial will provide evidence on the potential for nutritional interventions beginning prior to conception to promote healthy maternal and offspring outcomes.

**Trial registration:** ClinicalTrials.gov, identifier: NCT02509988, Universal Trial Number U1111-1171-8056. Registered on 16 July 2015. This is an academic-led study by the EpiGen Global Research Consortium.

**Keywords:** Preconception, Pregnancy, Randomised trial, Nutrition, Glucose metabolism, Metabolic diseases, Hyperglycemia, Body composition

## Background

There is now considerable concern about the maintenance of healthy glucose metabolism during pregnancy. This has arisen by extrapolation from the increasing number of women who develop type-2 diabetes during their reproductive years [1, 2]. Epidemiological studies show that children born to mothers with type-1 or type-2 diabetes also have a greater susceptibility to diabetes and obesity in later life [3, 4]. That this risk is related to intrauterine exposure to hyperglycaemia is shown by the observation that, among siblings, the risk of diabetes is higher in those born after the mother was diagnosed with diabetes [5]. These observations have been extended recently, as offspring exposed to even mild hyperglycaemia during pregnancy have increased adiposity and are at increased risk of later diabetes and cardio-metabolic disease [6, 7]. Through transgenerational perpetuation of the cycle of 'diabetes begetting diabetes', these factors are driving further escalation of the epidemic of noncommunicable diseases [8, 9].

The rising levels of maternal adiposity and obesity are of particular concern in both developed populations and those undergoing rapid socioeconomic transitions [1, 10, 11]. Maternal obesity is associated with increased risk of short-term adverse pregnancy outcomes as well as longer-term impact on offspring health [12], which have been postulated to be partly mediated by greater maternal insulin resistance and higher glycaemia. Both with and without clinically recognised pregnancy complications, evidence shows that a child of a mother with higher glycaemia per se may suffer from exposure to a suboptimal environment in utero, reducing the likelihood of a healthy body composition in the offspring and predisposing to increased childhood adiposity [13, 14]. Feeding pregnant rodents a high-fat diet gives rise to maternal obesity and hyperglycaemia, and offspring who become overweight demonstrate abnormalities similar to the human metabolic syndrome; these are associated with epigenetic changes such as altered deoxyribonucleic acid (DNA) methylation at specific genetic loci implicated in metabolic functions [15].

Pregnancy represents a state of relative maternal insulin resistance, which helps to promote the transfer of nutrients, such as glucose, fatty acids and amino acids, to the fetus [16]. Placental nutrient transfer is determined by the concentration gradient, blood flow and the operation of active and facilitated transporters [17]. However, in contrast to amino acids, there is no upper limit to placental transfer of glucose and consequent fetal adipose accretion as maternal blood glucose levels rise [13]; this may be viewed as adaptive, as, in the neonatal period, relative adiposity provides metabolic reserves for thermogenesis and critical organs in the event of inadequate maternal care [18]. However, excessive materno-placental glucose transfer is associated with fetal hyperinsulinemia and macrosomia [19, 20] and an increased risk of fatal obstructed labour, suggesting that the levels of glucose exposure of the fetus that are often now experienced are novel in evolutionary terms [21].

Gestational diabetes mellitus (GDM) can be envisaged as the more extreme outcome of physiological processes, when maternal insulin resistance is accentuated by the woman's own developmental, genetic and environmental circumstances: for example, women who themselves had a lower birth weight [22] or carry genetic variants associated with type-2 diabetes [23, 24] are at increased risk of GDM. Established risk factors for developing GDM include prepregnancy obesity [25], excessive gestational weight gain [26], advanced maternal age [27] and a previous pregnancy with GDM [28]. These factors are now increasingly common in women during their reproductive years with the evolutionary mismatched situation of over-nutrition and low levels of physical activity contributing not only to the rise in GDM but to the increasing prevalence of obesity and diabetes in their children, perpetuating a vicious cycle of disease. Such changes in growth potential and metabolic status may be mediated by inheritable epigenetic alterations occurring in utero [29]. For example, in Canadian first nation peoples, up to 30% of the incidence of type-2 diabetes has its origin in GDM in the previous generation [30]. Higher blood glucose levels in pregnancy carry risk of cardiovascular disease for both the mother as well as the child, a risk which increases with each pregnancy [31].

These findings have significant long-term implications for global public health. Now more than ever, effective

strategies for maintaining healthy maternal glucose metabolism in pregnancy are needed. Such strategies would benefit both the mother in terms of a healthy pregnancy and her own metabolic health, and the offspring in terms of promoting healthy body composition and wellbeing.

There are now data indicating that deficiency or low levels of certain micronutrients (vitamins $B_6$, $B_{12}$ and D, riboflavin) is extremely prevalent in pregnant women and has lasting effects on the offspring's risk of obesity, acting through epigenetic processes [32–34]. Evidence from South Asian pregnant women supports a role for the combination of maternal vitamin $B_{12}$ deficiency and folate sufficiency in promoting offspring adiposity, most likely mediated through impaired maternal glucose tolerance during pregnancy [35, 36]. Meta-analysis of observational studies strongly points to a role for maternal vitamin D deficiency in GDM [37], and additional vitamin D in pregnant women with GDM has been shown to have beneficial effects on glycaemia and total and low-density lipoprotein cholesterol (LDL)-cholesterol concentrations [38]. Low zinc intake and status has also been linked with maternal glycaemia [39], and we propose that maternal glucose tolerance may be on the causal pathway linking maternal micronutrient deficiency to offspring adiposity. Importantly, among the pregnant women who we studied in Southampton and Singapore there was a low prevalence of deficiency in folate and iron, the two most common micronutrients currently targeted for supplementation in pregnancy, and neither was associated with altered epigenetic adiposity biomarkers or with the child's adiposity.

Dietary myo-inositol is found in free form but can also be generated by microbial action in the gastrointestinal tract from food sources of phosphatidylinositol and phytic acid and its salts [40]. Myo-inositol is considered nonessential for mammals because it is synthesised de novo from glucose-6-phosphate in the kidney and other tissues [41, 42]. Abnormalities in its metabolism have been associated with insulin-resistance and its depletion has been frequently observed in tissues affected by diabetic microvascular and neurological complications in animal models and human subjects [43]. Our current understanding of the molecular pathways of insulin action led to the hypothesis that the nutritionally derived myo-inositol may increase insulin sensitivity by making available more phosphatidylinositol and potentially inositol glycan secondary messengers [44, 45]. An increasing number of publications suggest that myo-inositol may reduce insulin resistance during pregnancy [46–49].

Recent studies suggest that specific bacteria may positively influence cardiometabolic parameters, possibly through their interaction with the host and the effect of microbial-derived metabolites. There is now substantial evidence implicating a role for the gut microbiome in affecting glucose metabolism [50], and probiotics may modulate glucose tolerance through balancing gut microbiota, normalising increased intestinal permeability and lowering systemic and local low-grade inflammation [51]. There is preliminary evidence that a combination of probiotic strains during pregnancy may promote the maintenance of healthy glucose metabolism during pregnancy [52].

Taken together, there is strong support for new intervention studies commencing before pregnancy to provide myo-inositol and probiotics, and to improve maternal vitamin $B_6$, vitamin $B_{12}$, vitamin D and zinc status, aimed at optimising maternal glycaemia and glucose supply to the feto-placental unit to promote healthy offspring growth and body composition.

## Aim
This double-blind randomised controlled trial in groups of women from different ethnic groups in the UK, Singapore and New Zealand is designed to examine the hypothesis that, compared with standard supplementation, a nutritional drink that contains myo-inositol, probiotics and additional micronutrients, commencing before conception and continuing during pregnancy, will assist in the maintenance of healthy glucose metabolism in the mother and promote offspring health.

## Methods/design
### Trial design
Increasing evidence points to the preconception period and early pregnancy as a critical time when impaired maternal glucose tolerance may lead to biological alterations in the placenta and fetus that result in increased postnatal adiposity in the offspring [53]. As a consequence of this important evidence, our trial uniquely will focus on recruitment before conception and intervention both before and during pregnancy. Substantial experimental evidence from animal studies indicates that preconception is a critical period in the lifecourse for interventions to reduce later risk of metabolic dysregulation in the offspring. In humans, large cohort studies have demonstrated that preconception is a time when factors contributing to later ill-health begin to operate, as poor maternal and paternal diet and smoking before conception impact on development and long-term health of the offspring; to date, however, there are no population-based trials of preconception nutrition in developed communities.

The flow of the trial is shown in the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Figure (Fig. 1). See Additional file 1 for the SPIRIT checklist. Extensive biosampling and detailed phenotyping are embedded in the study with longitudinal assessments at

**Recruitment**

Self-referral of interested women who hear through public advertisement, social media, hospitals and primary care

Identification of participants planning to conceive in the next 6 months; 18 - 38 years old; living in Southampton, Singapore, Auckland

**Exclusion**: known DM (type 1 or 2), pregnant, lactating, require assisted conception (except those requiring only clomiphene or letrozole), on oral or implanted contraceptive, metformin, systemic steroids, anti-convulsant medication or treatment for HIV, Hepatitis B or C in past month, known serious food allergy

PCV1: **n = 1800**; OGTT and metabolic phenotyping, questionnaires (N, L, OH, MH, FH, PA, M, S), anthropometry, BIA, BP, biosampling (~,@,#,$)

**Preconception**

**Randomisation** (stratified by site and ethnicity)

**Control drink, n = 900**      **Intervention drink, n = 900**

**Preconception OGTT results from PCV1 known**
- NGT
- IFG (6.0-6.9 mmol/L) or IGT (7.8-11.0 mmol/L): given advice to maintain a healthy weight, eat well and be active. Antenatal care team will be informed of result when participant conceives.

**Withdrawal**: new type 2 DM (Fasting glucose ≥7.0 mmol/L or 2h post glucose ≥ 11.1 mmol/L)

**Withdrawal**: pregnancy before or at PCV2

PCV2 (21-42 days after PCV1): questionnaires (MSH), biosampling (~,@,#,$,^), DXA

PC Resupply visits (for 12 months from PCV2)

**Withdrawal**: not pregnant after 12 months from PCV2

**Pregnancy**

PGV1 (**7 weeks**): **n = 600**; USS, questionnaires (N, MSH, MTH, PA, M, S), anthropometry, BIA, BP, actigraphy, biosampling (~,@,#,$)

**Withdrawal**: pregnancy loss, ectopic or multiple pregnancy, perinatal demise

PGV2 (12 weeks): USS, biosample (@,#,$,^) collection

PGV3 (20 weeks): USS, questionnaires (N, MTH, PA, S), anthropometry, BIA, BP, biosampling (@,#,$)

PGV4 (28 weeks): OGTT; questionnaires (MTH, IIF, L, M, S), biosampling (~,@,#,$)

**Paternal visit**: **n = 600**; questionnaires (GH, MH, FH, L, M), anthropometry, BP, biosampling (~,@,#,$)

**Primary outcome**: OGTT plasma glucose - fasting, 1h and 2h post-glucose load
- NGT
- GDM (treatment according to local guidelines)

PGV5 (34 weeks): USS, questionnaires (N, MTH, PA, M, S), anthropometry, BIA, BP, biosampling (@,#,$,^,*)

BIRTH: **n = 550**; placenta, cord and cord blood sampling, subcutaneous fat (subset); antenatal and delivery outcomes
**Stop nutritional supplement**
**Mother**: questionnaires (MTH, N, MH)
**Infant**: anthropometry, biosampling (@,$,^)

**Post-delivery (up to 1 year from birth)**

PDV1 (1 week)
**Mother**: questionnaires (BM), biosampling (^,♥)
**Infant**: questionnaires (IFH), anthropometry, PeaPod, DXA (subset), biosampling ($)

PDV2 (3 weeks)
**Mother**: questionnaires (BM, N, M), biosampling ($,♥)
**Infant**: questionnaires (IFH, S), anthropometry, biosampling ($,^)

PDV3 (6 weeks)
**Mother**: questionnaires (BM, N, MH, S), BP, BIA, biosampling ($,♥)
**Infant**: questionnaires (IFH, S), anthropometry, PeaPod, BIA, biosampling (@,$)

PDV4 (3 months)
**Mother**: questionnaires (BM, N, MH, S), biosampling ($,♥)
**Infant**: questionnaires (IFH, BEBQ, S), anthropometry, biosampling (@,$,^)

PDV5 (6 months)
**Mother**: OGTT, questionnaires (GH, N, M, S), anthropometry, BIA, BP, biosampling (@,#,$), DXA, skin prick test
**Infant**: questionnaires (IFH), anthropometry, PeaPod, BIA, biosampling (@,$), skin prick test

PDV6 (12 months)
**Mother**: biosampling ($)
**Infant**: questionnaires (IFH), anthropometry, BIA, biosampling (@,$), skin prick test

**Withdrawal**: participant choice, loss to follow-up, <60% compliant, adverse reaction, medical reasons

**Fig. 1** (See legend on next page.)

(See figure on previous page.)
**Fig. 1** Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Figure: trial schema. Abbreviations: *PCV* preconception visit, *PC* preconception, *PGV* pregnancy visit, *PDV* post-delivery visit, *BIA* bioelectrical impedance analysis, *BP* blood pressure, *DM* diabetes mellitus, *DXA* dual-energy X-ray absorptiometry, *GDM* gestational diabetes, *HIV*, human immunodeficiency virus, *IFG* impaired fasting glucose, *IGT* impaired glucose tolerance, *NGT* normal glucose tolerance, *OGTT* oral glucose tolerance test, *USS*, ultrasound scan. Questionnaires: *BEBQ* baby eating behaviour, *BM* breast milk, *FH* family history, *GH* general health, *IFH* infant feeding and health, *IIF* intentions for infant feeding, *L* lifestyle, *M* mood (Edinburgh Postnatal Depression Scale, State-Trait Anxiety Inventory), *MH* medical history, *MSH* menstrual history, *MTH* maternal health, *N* nutrition/diet, *OH* obstetric history, *PA* physical activity, *S* sleep. Biosampling: # = blood, ♥ = breast milk, $ = buccal swabs, * = epithelial swabs, @ = hair, ^ = stool, ~ = urine

multiple time points starting from the preconception phase throughout pregnancy and into the first year post delivery. The biosampling and phenotyping will enable detailed mechanistic insights and characterisation of potential new interventions for investigation in future studies. Following informed consent at the first preconception visit, a baseline standard 75-g oral glucose tolerance test (OGTT) will be conducted, nutritional status, lifestyle, mood, body anthropometry and metabolic phenotype ascertained and biosampling undertaken, followed by randomisation to the intervention or control drink. At the second preconception visit a month later, further biosampling will be undertaken and body composition assessed by DXA (dual-energy X-ray absorptiometry) scanning. Regular in-person and phone contact will be made with participants to resupply control/intervention drinks, and to encourage retention and compliance during the preconception phase. Participants who become pregnant within a year of commencing the intervention or control drink will be seen around 7, 12, 20, 28 and 34 weeks of pregnancy for further phenotyping, biosampling and ultrasound scans assessing fetal growth and development. At 28 weeks' gestation, a standard 75-g OGTT will be repeated to ascertain the primary outcome. Normal antenatal care will be permitted during the trial. The fathers will be interviewed to ascertain paternal lifestyle and mood, their anthropometry measured and paternal biosamples collected. At birth, offspring cord blood, umbilical cord and placental samples will be collected. Neonatal body composition is assessed by anthropometry, air displacement plethysmography (PEA POD) and, in a subsample, by DXA scanning. Both breast- and formula-fed infants will be followed up when the infant is aged 1, 3 and 6 weeks, and 3, 6 and 12 months; infant feeding will be assessed in detail, biosamples collected and growth and wellbeing ascertained. Breast milk samples will be collected from a subset of participants in early infancy for nutrient and metabolic analysis. A maternal OGTT will be repeated again at 6 months postpartum and repeat biosamples collected. The site visits will be completed at the research and hospital facilities of the three sites in Auckland (University of Auckland, Auckland, Waitemata and Counties Manukau District Health Boards and Clinics, New Zealand), Singapore (National University Hospital and National University Health System Investigational Medicine

Unit) and Southampton (National Institute for Health Research Wellcome Trust Southampton Clinical Research Facility and Princess Anne Hospital, University Hospital Southampton, UK).

## Recruitment

Recruitment will be via self-referral of interested women who hear about the study via one or more of the following: (1) local site advertisements in social (e.g. Facebook) and general (e.g. radio, local newspapers, magazines, posters) media, (2) information brochures given to women engaging in community groups such as religious, culture-based or special-interest groups, (3) information brochures given to women identified through or attending primary medical care, family planning or hospital clinics (for this group, eligible women may be contacted by a research nurse if they give permission to the clinic to pass on their contact details for this purpose).

Inclusion criteria are women who meet the following:

- Aged 18–38 years
- Living in Southampton, Singapore or Auckland
- In Southampton and Auckland, planning to have future maternity care in Southampton and Auckland, respectively
- In Singapore, willing to deliver at the National University Hospital
- Women planning to conceive within 6 months (but conception up to 12 months after phenotyping will still be included)
- In Singapore only women of Chinese, Malay and Indian ethnicity, or of mixed Chinese/Malay/Indian ethnicity will be included
- Able to provide written, informed consent

Exclusion criteria are:

- Pregnant or lactating at recruitment (women who are currently breastfeeding will be excluded, but no washout period from the end of breastfeeding will be required before study start)
- Assisted fertility apart from those taking clomiphene or letrozole alone

- Women with pre-existing type-1 or type-2 diabetes (fasting plasma glucose concentration ≥7.0 mmol/L or post OGTT 2-h plasma glucose concentration ≥11.1 mmol/L)
- Oral or implanted contraception currently or in the last month, or with an intrauterine contraceptive device in situ
- Metformin or systemic steroids currently or in the last month
- Anticonvulsant medication currently or in the last month
- Treatment for HIV, Hepatitis B or C currently or in the last month
- Known serious food allergy

Withdrawal criteria are:

- The participant wishes to discontinue participation in the study
- The participant is unwilling or unable to comply with the protocol (including attendance at study visits, having study measures and biosampling)
- An overall uptake level of intervention/control nutritional drink of less than 60% evidenced by sachet counting
- The participant is pregnant before or at preconception visit 2
- The participant suffers a miscarriage (pregnancy loss before 24 weeks' gestation) or ectopic pregnancy. If the participant suffers a first-trimester pregnancy loss and wishes to re-join the study, she will be re-characterised as at the first baseline visit a month or more after a negative pregnancy test and will be assigned the nutritional drink with the same randomisation code as before
- The participant presents with a multiple pregnancy (twins or other multiples)
- The infant dies in the perinatal period (for post-birth secondary outcomes)
- The participant suffers an adverse reaction which is deemed by the investigator to be causally related to the intervention
- The participant is withdrawn at the discretion of the investigator for medical reasons

For participants who withdraw during the pregnancy phase of the study, consent will be obtained to follow up on key outcome measures from their medical records to enable comparison of the characteristics of withdrawn and studied participants.

### Randomisation procedure
At preconception clinic visit 1 all eligible participants will be randomised via the electronic study database to either the nutritional drink or the control drink. This database will assign each participant the appropriate code number that is consistent with either the intervention nutritional drink arm or the control drink arm. Randomisation will be stratified by site to ensure balanced allocation of participants across the two arms at each of the three sites, with further stratification by ethnicity. Investigational products will be blinded by the manufacturer with nonspeaking codes that do not allow deduction of the identity of intervention or control drinks. Investigators, staff performing the assessments and data analysts will remain blind to the identity of the allocation from the time of randomisation until either the participant is unblinded or database lock of the primary outcome occurs. If emergency unblinding is necessary, the process for this will be documented in the study Safety Monitoring Plan.

### The intervention
The Nutritional Intervention Preconception and During Pregnancy to Maintain Healthy Glucose Metabolism and Offspring Health (NiPPeR) intervention comprises: (1) a micronutrient-enriched nutritional drink containing myo-inositol, vitamin D, riboflavin, vitamin $B_6$, vitamin $B_{12}$ and zinc together with standard folic acid, iodine, calcium, β-carotene and iron; the quantities proposed are either standard amounts (myo-inositol [54]), enhanced amounts that are available in over-the-counter products (vitamins $B_6$, $B_{12}$, riboflavin), recommended daily allowance amounts in UK for pregnant women (vitamin D, zinc, folic acid, iodine) or minimal amounts for micronutrients linked with potential detrimental effects at higher doses (iron, β-carotene, calcium) and (2) probiotics (containing *Lactobacillus rhamnosus* NCC 4007 (CGMCC 1.3724) also known as LPR and *Bifidobacterium animalis* sp. *lactis* NCC 2818 (CNCM I-3446) also known as Bl818) [52]. The intervention group will be compared with a control group who receive a drink containing standard amounts of micronutrients that are part of routine pregnancy care (including folic acid, β-carotene, iron, calcium and iodine). The intervention is formulated as a powder in sachets to be made up in water immediately prior to consumption, with similar sensory characteristics for both the intervention and control drinks. The constituents of the intervention and control drinks are shown in Table 1, including the rationale for the amounts included. This trial uses established nutritional elements for which tolerability is well established. Confirmation that the trial is not a Clinical Trial of an Investigational Medicinal Product has been secured from MedSafe (New Zealand), Medicines and Healthcare products Regulatory Agency, MHRA (UK) and the Health Sciences Authority (Singapore).

**Table 1** Constituents of the intervention and control drinks

| Intervention group | Daily amount | Rationale |
|---|---|---|
| Myo-inositol | 4 g | Improves glucose metabolism and preliminary data suggest may maintain healthy glucose metabolism in pregnancy; dose safely used in pregnancy |
| Vitamin $D_3$ | 400 IU | Deficiency highly prevalent and linked with glucose metabolism in pregnancy and offspring postnatal adiposity gain; dose sufficient to reduce insufficiency while avoiding potential concerns re adverse effects at high doses. Omission from control group supported by a *Lancet* study [56] |
| Vitamin $B_6$ | 2.6 mg | Deficiency highly prevalent and linked with glucose metabolism in pregnancy and offspring postnatal adiposity gain [33]; dose sufficient to rectify deficiency and present in current over-the-counter products (e.g. Elevit). Omission from control group supported by usual clinical practice |
| Vitamin $B_{12}$ | 5.2 μg | Deficiency highly prevalent and linked with glucose metabolism in pregnancy and offspring postnatal adiposity gain; dose sufficient to rectify deficiency and less than that in current over-the-counter products (e.g. Elevit). Omission from control group supported by usual clinical practice |
| Riboflavin | 1.8 mg | Low intake highly prevalent and linked with offspring postnatal adiposity gain [34]; dose sufficient to rectify deficiency and present in current over-the-counter products (e.g. Elevit). Omission from control group supported by usual clinical practice |
| Zinc | 10 mg | Deficiency highly prevalent and linked with offspring postnatal adiposity gain [unpublished]; dose sufficient to rectify deficiency and present in current over-the-counter products (e.g. Elevit). Omission from control group supported by usual clinical practice |
| β-carotene | 720 μg (15% of vitamin A requirements, as retinol equivalents) | Required in pregnancy in some jurisdictions |
| Folic acid | 400 μg | Standard preconception recommendation |
| Iron | 12 mg | Iron is routinely prescribed and taken before/during pregnancy, though without convincing evidence of benefit; low dose included to lessen likelihood of additionally receiving a high-dose iron product, which has been linked with glucose metabolism in pregnancy |
| Calcium | 150 mg | A low dose of calcium is commonly taken before/during pregnancy; provision of this will lessen the likelihood of additional products being taken |
| Iodine | 150 μg | Standard preconception recommendation |
| Probiotic | | Taking a combination of two probiotics has been linked with maintenance of healthy glucose metabolism in pregnancy. Probiotic capsule containing $>1 \times 10^9$ cfu each of *Lactobacillus rhamnosus* NCC 4007 (CGMCC 1.3724) also known as LPR and *Bifidobacterium animalis* sp. *lactis* NCC 2818 (CNCM I-3446) also known as Bl818 |
| **Control group** | | |
| Folic acid | 400 μg | Standard preconception recommendation |
| Iron | 12 mg | Iron is routinely prescribed and taken before/during pregnancy, though without convincing evidence of benefit; low dose included to lessen likelihood of additionally receiving a high-dose iron product, which has been linked with glucose metabolism in pregnancy |
| Calcium | 150 mg | A low dose of calcium is commonly taken before/during pregnancy; provision of this will lessen the likelihood of additional products being taken |
| Iodine | 150 μg | Standard preconception recommendation http://www.cdc.gov/preconception/documents/clinical-content_womensnutritionfactsheet3.pdf |
| β-carotene | 720 μg (15% of vitamin A requirements, as retinol equivalents) | Required in pregnancy in some jurisdictions |

## Outcome measurements

The primary analysis will adjust for site, ethnicity and preconception glycaemia to account for potential imbalance between treatment arms amongst pregnancies which reach 28 weeks' gestation, examining for differences in means between the control and intervention groups for the primary endpoint, specifically the fasting and/or 60-min and/or 2-h glucose concentrations following a 75-g OGTT at 28 weeks' gestation. Maternal glucose metabolism at 28 weeks' gestation has been chosen as the primary outcome as there is evidence that maintaining normal carbohydrate metabolism during pregnancy is associated with a healthier body composition, a reduced risk of obesity and potentially promotion of allergic/respiratory health in the children [55], alongside the recognised pregnancy benefits for the mother.

Secondary maternal outcomes of the initial phase of the NiPPeR study are:

1. Maintenance of a healthy pregnancy, including normal duration of gestation (at least 37 weeks' gestation), absence of GDM (defined using the International Association of the Diabetes and Pregnancy Study Groups criteria: glucose cut-off values of ≥5.1 mmol/L for fasting plasma glucose, and/or ≥10.0 mmol/L for 1-h and/or ≥8.5 mmol/L for 2-h post load), change in fasting glucose and OGTT glucose area under the curve from preconception baseline to 28 weeks' gestation, maternal wellbeing/mood, absence of excessive nausea and vomiting, adequate pregnancy weight gain (Institute of Medicine criteria) and vaginal delivery rates

2. Reduction in maternal micronutrient insufficiency, specifically less riboflavin, vitamin $B_6$, vitamin $B_{12}$, zinc and vitamin D insufficiency, before and during pregnancy

3. Alteration in gut microbiota consistent with enhanced wellbeing

4. Alteration in maternal metabolomic and epigenetic biomarkers consistent with improved maternal and/or offspring wellbeing

5. Enhancement of breast milk micronutrient content, altered immunological factors, epigenetic and metabolomic profiles (subsample) and maintenance of healthy lactogenesis

Secondary offspring outcomes of the initial phase of the NiPPeR study are:

1. Neonatal adiposity measured by PEA POD
2. Birthweight 2500–4000 g, size for gestational age at birth and customised birthweight centile
3. Reduced adiposity gain during infancy, analysed taking account of infant feeding
4. Reduction in cord blood C-peptide as a marker of overall glycaemia during gestation
5. Promotion of offspring wellbeing and healthy cardiometabolic risk factors, including visceral adiposity and markers of insulin resistance, during infancy
6. Alteration in offspring metabolomic and epigenetic biomarkers in perinatal samples, consistent with improved infant metabolic and allergic wellbeing
7. Alteration in gut microbiota to a microbiota associated with infant metabolic and allergic wellbeing

## Data and biosample collection

Study data will be collected by trained research staff using an access-controlled, web-based database (MedSciNet, Stockholm) managed with support from the data management staff of the MRC Lifecourse Epidemiology Unit and the Singapore Institute for Clinical Sciences.

The study database will not hold personal information, which will be stored separately at each institution with access limited to study coordinators. Data from the web-based database will be downloaded via a dedicated computer and stored securely on the MRC Lifecourse Epidemiology Unit's servers in the UK. Data extracts will be provided for analysis by the study researchers treating data from all three sites as a single study. All data will be kept in accordance with the UK Data Protection Act, and applicable regulations and guidance of each country and institution.

Biological samples will be collected and processed using standardised consumables, equipment and protocols across the three sites and will be being stored in accordance with the UK Human Tissue Act or equivalent at each institution in appropriately regulated biobanks. The study database allows management of the samples. All analysis will be carried out on anonymised data and samples. Accredited laboratories will be used for measurement of the primary outcome of plasma glucose concentrations.

## Study management and governance

This double-blind randomised controlled trial is led by investigators from the EpiGen Global Research Consortium, an academic research consortium comprising representatives from the University of Southampton (MRC Lifecourse Epidemiology Unit and Institute of Developmental Sciences), University of Auckland (Liggins Institute), the Growth, Development, and Metabolism Programme of the Singapore Institute for Clinical Sciences (an operating unit of A*STAR) and the National University of Singapore (Translational and Clinical Research Flagship Programme, 'Developmental pathways to metabolic disease'), together with the Singapore National University Health System. Scientists from the Nestlé Research Centre (Nestec) provided advice on aspects of the intervention formulation, study design and specific laboratory analyses.

The UK sponsor of the project is the University of Southampton; the New Zealand sponsor of the project is Auckland UniServices Limited; the Singapore sponsor of the project is the National University Hospital Singapore. The sponsors are indemnified for any harms arising from trial participation and will approve protocol amendments for which ethics approval has been secured, alongside update of trial registry entries. Trial oversight will be provided by an Independent Data Monitoring and Safety Committee. The day-to-day running of the study will be through the Trial Management Group, consisting of the principal investigators and the clinical trial operations director, who will be responsible for all decisions on the study management and delivery.

Monitoring will be carried out several times per year by an external, independent monitor at each site, following the risk-based monitoring plan established for the study, overseen by the study sponsor. Safety reporting will be in accordance with the study Safety Monitoring Plan and all events will be recorded in the study database. An Independent Data Monitoring and Safety Committee has been established for the trial. This committee is independent from the sponsor and competing interests and will meet annually and oversee all ethical and safety issues in accordance with current regulations and MRC guidelines for Data Monitoring Committees. The Committee Charter is available from the clinical trial operations director, who will coordinate and review activity across sites.

### Statistical analysis
The primary analysis will be according to the intention-to-treat principle. Additionally, a priori sensitivity analyses will be undertaken, omitting participants withdrawn as a consequence of reluctance to continue with the trial, conception after taking the nutritional drink for less than 21 days, less than 60% uptake with the intervention (evidenced by sachet counting), not conceiving after 12 months of participation or not achieving a pregnancy of more than 28 weeks. Further sensitivity analyses using a 'per protocol' or an 'as treated' analysis will be performed if deemed appropriate by the trial statisticians. For analysis of the primary endpoint only: if exploratory analysis reveals the presence of outliers, as identified by independent experts and/or the trial statisticians, sensitivity analysis will be performed excluding these outliers. Analyses will be specified in the study statistical analysis plan finalised by the Trial Management Group before unblinding the data. The influence of missing data will be examined using multiple imputation techniques. There are no formal planned interim analyses of the primary outcome, but progress reports on all data issues will be presented to the Independent Data Monitoring and Safety Committee, who will agree their charter at their first meeting. Analyses of the baseline phenotypic data that do not require unblinding will be undertaken. We will build prognostic models using baseline covariates on the primary outcome of maternal glucose tolerance in pregnancy. Planned subgroup analyses will include stratification by ethnicity across study sites.

### Power calculations
By studying up to 900 prepregnant participants in each of the intervention and control groups, a total of 600 pregnancies and 500 live births is conservatively anticipated, following attrition from miscarriage, ectopic pregnancy, perinatal demise, multiple pregnancy, voluntary participant withdrawal, inability to comply with the protocol, withdrawal for medical reasons at the discretion of the investigator and loss-to-follow-up. A study of 250 pregnancies with 28-week OGTT data in each group has 89% power to detect a 0.1-mmol/L reduction in fasting plasma glucose and 84% power to detect a 0.3-mmol/L reduction in 2-h plasma glucose at the 5% level of significance. In the Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study such changes in glucose concentrations were associated with >10% changes in the odds of macrosomia and sum of neonatal skinfolds >90th centile and with a >20% change in cord C-peptide >90th centile [6]. As a further illustration of statistical power, using the distribution of 60-min plasma glucose in the HAPO study, a study of 250 participants in each of the two groups has 80% power to detect a difference of ≥0.43 mmol/L in 60-min glucose at $P < 0.05$. A study of 300 pregnancies in each arm will have an 80% power to detect a reduction in the mean plasma glucose of 0.12, 0.45 and 0.34 mmol/L at fasting, 60 min and 2 h, respectively, with an alpha of 0.017 taking into account multiple testing.

## Discussion
This double-blind randomised controlled trial in groups of women from different ethnic groups in the UK, Singapore and New Zealand is designed to examine the hypothesis that a nutritional drink, commencing before conception and continuing during pregnancy, will assist in the maintenance of healthy glucose metabolism in the mother and promote offspring health. Improved maternal nutrition and glycaemic control before and during pregnancy has benefits for the health of the mother and her offspring, including healthy offspring body composition and decreased risks of childhood obesity and allergies. The intervention group will receive a nutritional drink enriched with micronutrients, myo-inositol and probiotics, and the control group will receive a drink enriched with standard micronutrients. The potential for adverse effects of the intervention is low as the probiotic and myo-inositol are thought to exert their main effects through physiological modulation of maternal metabolism rather than through direct effects on the fetus and, while the amounts of micronutrients in the nutritional drink are sufficient to rectify maternal deficiency, they do not exceed UK, Singapore and New Zealand safe upper limits.

The trial commences preconception as studies by Catalano et al. [53] suggest that a major part of the risk of macrosomia originates in early pregnancy/prepregnancy and adverse pregnancy outcomes are associated with poor maternal nutrition at conception; maternal insulin resistance and hyperglycaemia in the very earliest stages of pregnancy alter placental anatomy and physiology in ways

that persistently affect transplacental fetal nutrient supply and fetal fat accretion, as well as bilateral maternal-feto-placental cross-talk, with consequences for later postnatal health. As a consequence, intervention commencing in established pregnancy can only partially influence fetal growth and development. The earlier that maternal glycaemia is optimised and micronutrient deficiencies prevented, the greater the likelihood of maintaining fetal and postnatal health and wellbeing. Many influential governmental and nongovernmental organisations are now stressing the importance of optimising preconception nutrition in general terms but as yet, other than folic acid to prevent neural tube defects, there are few preconception interventions that are recognised as promoting health benefits for the mother or offspring, and none, apart from folic acid, has a robust evidence base.

In the initial phase of the NiPPeR study a broad range of maternal nutritional assessments, potential epigenetic mechanisms and secondary measures relating to pregnancy outcomes and infant growth, body composition and wellbeing will be characterised and are detailed in this protocol.

The extensive biosampling and detailed phenotyping embedded in the study before, during and after pregnancy will provide an important discovery pipeline for the development of novel biomarkers of maternal and offspring wellbeing, and lead to new interventions and future guidelines to promote healthy human growth and development. A range of biological samples collected at multiple time points before, during and after pregnancy in the mother and offspring enables a systems biology approach to understanding the complex interaction of factors that determine maternal and infant wellbeing. Both individually and collectively, the control and intervention arms will provide extensive information that will deliver new knowledge on how maternal nutrition and metabolic state can promote offspring health. The research will also benefit from insights arising from other studies by the EpiGen Global Research Consortium in the UK, Singapore and New Zealand. The ethnicities of the participants in the study will allow broad extrapolation of the findings, and enable subsequent smaller-scale studies in other jurisdictions, such as China and India, as appropriate. The partners have extensive experience of following up prospective mother-offspring cohorts, maternal, obstetrical, fetal and infant medicine and health care, and detailed characterisation of a comprehensive set of health and wellbeing outcomes through infancy and childhood will be undertaken. The data collected will allow determination of the contributions of nutritional and lifestyle factors, socioeconomic status, ethnicity, genetics, transcriptomics, epigenomics, metabolomics and metagenomics to maintaining healthy glucose metabolism in pregnancy and promoting healthy growth, body composition and wellbeing in the offspring.

## Trial status

Recruitment for the trial commenced on 3 August 2015; more than half of the participants have been recruited within the following 12 months and recruitment remains ongoing in October 2016. Participants have already progressed through the randomisation and pregnancy phases of the study and initial deliveries have occurred in all three sites.

## Additional file

Additional file 1: SPIRIT 2013 Checklist: recommended items to address in a clinical trial protocol and related documents*. (DOC 121 kb)

operating procedures and delivery of the programme by SYC, WSC and the individuals in the NiPPeR Study Group. As chief investigator, KMG leads research planning and delivery across all three sites. KMG, WSC, SYC, PNB and CYS are principal investigators on the study Trial Management Group, which manages study delivery at the three sites, data analysis and interpretation and manuscript preparation. The manuscript was drafted by KMG, WSC, SYC, PNB and CYS. All authors, including those in the NiPPeR Study Group, have contributed to the draft protocol, approved the final manuscript and gave consent for its publication.

## Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

### Author details
[1]NIHR Southampton Biomedical Research Centre, University Hospital Southampton, NHS Foundation Trust, Southampton, UK. [2]MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Mailpoint 95, Southampton SO16 6YD, UK. [3]Liggins Institute, University of Auckland, Auckland, New Zealand. [4]A Better Start, New Zealand National Science Challenge, Auckland, New Zealand. [5]Department of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore and National University Health System, Singapore, Singapore. [6]Singapore Institute for Clinical Sciences, Agency for Science, Technology and Research, Singapore, Singapore. [7]College of Medicine, Biological Sciences and Psychology, University of Leicester, Leicester, UK.

### References
1. Ferrara A. Increasing prevalence of gestational diabetes mellitus: a public health perspective. Diabetes Care. 2007;30(Suppl 2):S141–6.
2. Reece EA, Leguizamon G, Wiznitzer A. Gestational diabetes: the need for a common ground. Lancet. 2009;373:1789–97.
3. Poston L. Developmental programming and diabetes—The human experience and insight from animal models. Best Pract Res Clin Endocrinol Metab. 2010;24:541–52.
4. Simeoni U, Barker DJ. Offspring of diabetic pregnancy: long-term outcomes. Semin Fetal Neonatal Med. 2009;14:119–24.
5. Dabelea D, Hanson RL, Lindsay RS, Pettitt DJ, Imperatore G, Gabir MM, Roumain J, Bennett PH, Knowler WC. Intrauterine exposure to diabetes conveys risks for type 2 diabetes and obesity: a study of discordant sibships. Diabetes. 2000;49:2208–11.
6. Hyperglycemia and Adverse Pregnancy Outcome (HAPO). Study: associations with neonatal anthropometrics. Diabetes. 2009;58:453–9.
7. Tam WH, Ma RC, Yang X, Li AM, Ko GT, Kong AP, Lao TT, Chan MH, Lam CW, Chan JC. Glucose intolerance and cardiometabolic risk in adolescents exposed to maternal gestational diabetes: a 15-year follow-up study. Diabetes Care. 2010;33:1382–4.
8. Ma RC, Chan JC. Pregnancy and diabetes scenario around the world: China. Int J Gynaecol Obstet. 2009;104(Suppl 1):S42–5.
9. Yajnik CS. Fetal programming of diabetes: still so much to learn! Diabetes Care. 2010;33:1146–8.
10. Ramachandran A, Ma RC, Snehalatha C. Diabetes in Asia. Lancet. 2010;375:408–18.
11. Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, Hu FB. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009;301:2129–40.
12. Godfrey KM, Reynolds RM, Prescott SL, Nyirenda M, Jaddoe VWV, Eriksson JG, Broekman BFP. The influence of maternal obesity on the long-term health of the offspring. Lancet Diabetes Endocrinol. 2017;5:53–64.
13. Aris IM, Soh SE, Tint MT, Liang S, Chinnadurai A, Saw SM, Rajadurai VS, Kwek K, Meaney MJ, Godfrey KM, Gluckman PD, Yap FK, Chong YS, Lee YS. Effect of maternal glycemia on neonatal adiposity in a multiethnic Asian birth cohort. J Clin Endocrinol Metab. 2014;99:240–7.
14. Zhao P, Liu E, Qiao Y, Katzmarzyk PT, Chaput JP, Fogelholm M, Johnson WD, Kuriyan R, Kurpad A, Lambert EV, Maher C, Maia JA, Matsudo V, Olds T, Onywera V, Sarmiento OL, Standage M, Tremblay MS, Tudor-Locke C, Hu G, ISCOLE Research Group. Maternal gestational diabetes and childhood obesity at age 9–11: results of a multinational study. Diabetologia. 2016;59:2339–48.
15. Dudley KJ, Sloboda DM, Connor KL, Beltrand J, Vickers MH. Offspring of mothers fed a high fat diet display hepatic cell cycle inhibition and associated changes in gene expression and DNA methylation. PLoS One. 2011;6:e21662.
16. Lain KY, Catalano PM. Metabolic changes in pregnancy. Clin Obstet Gynecol. 2007;50:938–48.
17. Lewis RM, Demmelmair H, Gaillard R, Godfrey KM, Hauguel-de Mouzon S, Huppertz B, Larque E, Saffery R, Symonds ME, Desoye G. The placental exposome: placental determinants of fetal adiposity and postnatal body composition. Ann Nutr Metab. 2013;63:208–15.
18. Kuzawa CW. Fetal origins of developmental plasticity: are fetal cues reliable predictors of future nutritional environments? Am J Hum Biol. 2005;17:5–21.
19. Susa JB, Schwartz R. Effects of hyperinsulinemia in the primate fetus. Diabetes. 1985;34(Suppl 2):36–41.
20. de Santis MS, Taricco E, Radaelli T, Spada E, Rigano S, Ferrazzi E, Milani S, Cetin I. Growth of fetal lean mass and fetal fat mass in gestational diabetes. Ultrasound Obstet Gynecol. 2010;36:328–37.
21. Godfrey KM, Haugen G, Kiserud T, Inskip HM, Cooper C, Harvey NCW, Crozier SR, Robinson SM, Davies L, the Southampton Women's Survey Study Group, Hanson MA. Fetal liver blood flow distribution: role in human developmental strategy to prioritize fat deposition versus brain development. PLoS One. 2012;7:e41759.
22. Egeland GM, Skjaerven R, Irgens LM. Birth characteristics of women who develop gestational diabetes: population based study. BMJ. 2000;321:546–7.
23. Lauenborg J, Grarup N, Damm P, Borch-Johnsen K, Jorgensen T, Pedersen O, Hansen T. Common type 2 diabetes risk gene variants associate with gestational diabetes. J Clin Endocrinol Metab. 2009;94:145–50.
24. Konig M, Shuldiner AR. The genetic interface between gestational diabetes and type 2 diabetes. J Matern Fetal Neonatal Med. 2011;25(1):36–40.
25. Graves E, Hill DJ, Evers S, et al. The impact of abnormal glucose tolerance and obesity on fetal growth. J Diabetes Res. 2015;2015:847674.
26. Gibson KS, Waters TP, Catalano PM. Maternal weight gain in women who develop gestational diabetes mellitus. Obstet Gynecol. 2012;119:560–5.
27. Solomon CG, Willett WC, Carey VJ, et al. A prospective study of pregravid determinants of gestational diabetes mellitus. JAMA. 1997;278:1078–83.
28. Schwartz N, Nachum Z, Green MS. The prevalence of gestational diabetes mellitus recurrence—effect of ethnicity and parity: a meta-analysis. Am J Obstet Gynecol. 2015;213:310–7.
29. Godfrey KM, Costello PM, Lillycrop KA. The developmental environment, epigenetic biomarkers and long-term health. J Dev Orig Health Dis. 2015;6:399–406.

30. Dowse GK, Zimmet PZ, Finch CF, Collins VR. Decline in incidence of epidemic glucose intolerance in Nauruans: implications for the 'thrifty genotype'. Am J Epidemiol. 1991;133:1093–104.

31. Sattar N, Greer IA. Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening? BMJ. 2002;325:157–60.

32. Crozier SR, Harvey NC, Inskip HM, Godfrey KM, Cooper C, Robinson SM, SWS Study Group. Maternal vitamin D status in pregnancy is associated with adiposity in the offspring. Findings from the Southampton Women's Survey. Am J Clin Nutr. 2012;96:57–63.

33. Godfrey KM, Sheppard A, Gluckman PD, Lillycrop KA, Burdge GC, McLean C, Rodford J, Slater-Jefferies JL, Garratt E, Crozier SR, Emerald BS, Gale CR, Inskip HM, Cooper C, Hanson MA. Epigenetic gene promoter methylation at birth is associated with child's later adiposity. Diabetes. 2011;60:1528–34.

34. Childs C, Titcombe P, Crozier S, Barton S, Harvey N, Cooper C, Inskip H, Godfrey K. Low B-vitamin status during pregnancy is associated with greater offspring adiposity in childhood. J Dev Orig Health Dis. 2015;6(Suppl 2):S36.

35. Yajnik CS, Deshpande SS, Jackson AA, Refsum H, Rao S, Fisher DJ, Bhat DS, Naik SS, Coyaji KJ, Joglekar CV, Joshi N, Lubree HG, Deshpande VU, Rege SS, Fall CH. Vitamin B$_{12}$ and folate concentrations during pregnancy and insulin resistance in the offspring: the Pune Maternal Nutrition Study. Diabetologia. 2008;51:29–38.

36. Krishnaveni GV, Hill JC, Veena SR, Bhat DS, Wills AK, Karat CL, Yajnik CS, Fall CH. Low plasma vitamin B$_{12}$ in pregnancy is associated with gestational 'diabesity' and later diabetes. Diabetologia. 2009;52:2350–8.

37. Lu M, Xu Y, Lv L, Zhang M. Association between vitamin D status and the risk of gestational diabetes mellitus: a meta-analysis. Arch Gynecol Obstet. 2016;293:959–66.

38. Asemi Z, Hashemi T, Karamali M, Samimi M, Esmaillzadeh A. Effects of vitamin D supplementation on glucose metabolism, lipid concentrations, inflammation, and oxidative stress in gestational diabetes: a double-blind randomized controlled clinical trial. Am J Clin Nutr. 2013;98:1425–32.

39. Bo S, Lezo A, Menato G, Gallo ML, Bardelli C, Signorile A, Berutti C, Massobrio M, Pagano GF. Gestational hyperglycemia, zinc, selenium, and antioxidant vitamins. Nutrition. 2005;21:186–91.

40. Schlemmer U, Frolich W, Prieto RM, et al. Phytate in foods and significance for humans: food sources, intake, processing, bioavailability, protective role and analysis. Mol Nutr Food Res. 2009;53(Suppl 2):S330–75.

41. Clements RS, Diethelm AG. The metabolism of myo-inositol by the human kidney. J Lab Clin Med. 1979;93:210–9.

42. Hauser G, Finelli VN. The biosynthesis of free and phosphatide myo-inositol from glucose by mammalian tissue slices. J Biol Chem. 1963;238:3224–8.

43. Croze ML, Soulage CO. Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie. 2013;95:1811–27.

44. Coustan DR. Can a dietary supplement prevent gestational diabetes mellitus? Diabetes Care. 2013;36:777–9.

45. Foster SR, Omoruyi FO, Bustamante J, Lindo RL, Dilworth LL. The effect of combined inositol hexakisphosphate and inositol supplement in streptozotocin-induced type 2 diabetic rats. Int J Exp Pathol. 2016;97:397-407.

46. D'Anna R, Scilipoti A, Giordano D, Caruso C, Cannata ML, Interdonato ML, Corrado F, Di Benedetto A. myo-Inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care. 2013;36:854–7.

47. Corrado F, D'Anna R, Di Vieste G, Giordano D, Pintaudi B, Santamaria A, Di Benedetto A. The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes. Diabet Med. 2011;28:972–5.

48. D'Anna R, Di Benedetto V, Rizzo P, Raffone E, Interdonato ML, Corrado F, Di Benedetto A. Myo-inositol may prevent gestational diabetes in PCOS women. Gynecol Endocrinol. 2012;28:440–2.

49. Matarrelli B, Vitacolonna E, D'angelo M, Pavone G, Mattei PA, Liberati M, Celentano C. Effect of dietary myo-inositol supplementation in pregnancy on the incidence of maternal gestational diabetes mellitus and fetal outcomes: a randomized controlled trial. J Matern Fetal Neonatal Med. 2013;26:967–72.

50. Cani PD, Geurts L, Matamoros S, Plovier H, Duparc T. Glucose metabolism: focus on gut microbiota, the endocannabinoid system and beyond. Diabetes Metab. 2014;40:246–57.

51. Isolauri E, Rautava S, Collado MC, Salminen S. Role of probiotics in reducing the risk of gestational diabetes. Diabetes Obes Metab. 2015;17:713–9.

52. Luoto R, Laitinen K, Nermes M, Isolauri E. Impact of maternal probiotic-supplemented dietary counselling on pregnancy outcome and prenatal and postnatal growth: a double-blind, placebo-controlled study. Br J Nutr. 2010;103:1792–9.

53. Catalano P, deMouzon SH. Maternal obesity and metabolic risk to the offspring: why lifestyle interventions may have not achieved the desired outcomes. Int J Obes. 2015;39:642–9.

54. Norwegian Scientific Committee for Food Safety. http://www.english.vkm.no/dav/dcbbd8d80c.pdf.

55. Kumar R, Ouyang F, Story RE, Pongracic JA, Hong X, Wang G, Pearson C, Ortiz K, Bauchner H, Wang X. Gestational diabetes, atopic dermatitis, and allergen sensitization in early childhood. J Allergy Clin Immunol. 2009;124:1031–8.

56. Lawlor DA, Wills AK, Fraser A, Sayers A, Fraser WD, Tobias JH. Association of maternal vitamin D status during pregnancy with bone-mineral content in offspring: a prospective cohort study. Lancet. 2013;381:2176–83.